SCHEMBL24208141

SCHEMBL24208141

O=C(c1ccccc1F)N1CC2CCN(Cc3c(-c4ccc(Cl)cc4)nc4ncccn34)CC1C2

nearest known ligand 0.79

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ KCNK3 O14649 20/20 0.79
▸ KCNK9 Q9NPC2 20/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24208176 0.92 KCNK3 (0.75) KCNK3KCNK9
SCHEMBL29458057 0.88 KCNK3 (1.00) KCNK3KCNK9
SCHEMBL20587832 0.88 KCNK3 (1.00) KCNK3KCNK9
SCHEMBL22001699 0.87 KCNK3 (1.00) KCNK3KCNK9
SCHEMBL22636106 0.86 KCNK3 (1.00) KCNK3KCNK9
SCHEMBL29458058 0.86 KCNK3 (1.00) KCNK3KCNK9
SCHEMBL24208185 0.86 KCNK3 (0.75) KCNK3KCNK9
SCHEMBL22636037 0.84 KCNK3 (1.00) KCNK3KCNK9
SCHEMBL22635894 0.84 KCNK3 (1.00) KCNK3KCNK9
SCHEMBL29432668 0.84 KCNK3 (1.00) KCNK3KCNK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220017540-A1 DIAZABICYCLIC SUBSTITUTED IMIDAZOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF BREATHING DISORDERS BAYER AKTIENGESELLSCHAFT (DE) 2022-01-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220017540-A1 DIAZABICYCLIC SUBSTITUTED IMIDAZOPYRIMIDINES AND THEIR USE FOR THE TREATMENT OF BREATHING DISORDERS HIF1AN, QDPR, HNMT KCNK3 3529/4885KCNK9 4195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback